A case of plasmacytic hyperplasia arising in a kidney allograft salvaged with immunosuppression reduction alone

Clinical Transplantation, Supplement

Volumn 18, Issue 11, 2004, Pages 50-53

  Harada, Hiroshi ^a   Miura, M ^a   Shimoda, N ^a   Seki, T ^a   Togashi, M ^a   Ogawa, Y ^a   Takada, A ^a   Tahara, M ^a   Sato, H ^a   Hirano, T ^a  

^a SAPPORO CITY GENERAL HOSPITAL   (Japan)

Author keywords

Graft; Plasmacytic hyperplasia; Post transplant lymphoproliferative disorder; Renal transplantation

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ACUTE DISEASE; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CELL INFILTRATION; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; PLASMA CELL; PLASMACYTIC HYPERPLASIA; PRIORITY JOURNAL; RADIODIAGNOSIS; SALVAGE THERAPY;

EID: 4544266031     PISSN: 13996738     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00248.x     Document Type: Article

References (10)

1. Petit B, Le Meur Y, Jaccard A et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002: 73: 265.
2. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997: 14: 8.
3. Meehan SM, Domer P, Josephson M et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol 2001: 32: 205.
4. Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997: 14: 15.
5. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997: 14: 2.
6. Muti G, Klersy C, Baldanti F et al. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 2003: 122: 927.
7. Muti G, Cantoni S, Oreste P et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002: 87: 67.
8. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998: 82: 1978.
9. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995: 85: 552.
10. Dunphy CH, Galambos C, Polski JM et al. Extranodal posttransplant plasmacytic hyperplasia with subsequent posttransplant plasmacytic malignancy: six-year interval case report and review of the literature. Arch Pathol Lab Med 2002: 126: 351.